Alpha 2.0
Login Register
» Articles » PMID: 33223405

Are Diabetes and Its Medications Risk Factors for the Development of COVID-19? Data from a Population-based Study in Sicily

Overview
Journal Nutr Metab Cardiovasc Dis
Publisher Elsevier
Specialties Cardiology & Vascular Diseases
Endocrinology
Nutritional Sciences
Date 2020 Nov 23
PMID 33223405
Citations 25
Authors
G Antonio Silverii
Matteo Monami
Achille Cernigliaro
Enrica Vigneri
Valentina Guarnotta
Salvatore Scondotto
Vincenza A Allotta
Michela Conti
Carla Giordano
Edoardo Mannucci
Affiliations
Soon will be listed here.
Abstract

Background And Aims: Diabetes mellitus (DM) has been associated with higher incidence of severe cases of COVID-19 in hospitalized patients, but it is unknown whether DM is a risk factor for the overall COVID-19 incidence. The aim of present study was to investigate whether there is an association of DM with COVID-19 prevalence and case fatality, and between different DM medications and risk for COVID-19 infection and death.

Methods And Results: retrospective observational study on all SARS-CoV-2 positive (SARS-CoV-2) cases and deaths in Sicily up to 2020, May 14th. No difference in COVID-19 prevalence was found between people with and without DM (RR 0.92 [0.79-1.09]). Case fatality was significantly higher in SARS-CoV-2 with DM (RR 4.5 [3.55-5.71]). No diabetes medication was associated with differences in risk for SARS-Cov2 infection.

Conclusions: in Sicily, DM was not a risk factor for COVID-19 infection, whereas it was associated with a higher case fatality.

Citing Articles

Is Metformin Use Associated with a More Favorable COVID-19 Course in People with Diabetes?.

Silverii G, Fumagalli C, Rozzini R, Milani M, Mannucci E, Marchionni N J Clin Med. 2024; 13(7).

PMID: 38610639 PMC: 11012895. DOI: 10.3390/jcm13071874.

Association of anti-diabetic drugs and COVID-19 outcomes in patients with diabetes mellitus type 2 and cardiomyopathy.

Dimnjakovic J, Buble T, Ivanko P, Pristas I, Brborovic O, Brborovic H Sci Rep. 2024; 14(1):7227.

PMID: 38538694 PMC: 10973387. DOI: 10.1038/s41598-024-57871-9.

Stress Hyperglycemia, Diabetes Mellitus and COVID-19 Infection: Risk Factors, Clinical Outcomes and Post-Discharge Implications.

Gerganova A, Assyov Y, Kamenov Z Front Clin Diabetes Healthc. 2023; 3:826006.

PMID: 36992767 PMC: 10012081. DOI: 10.3389/fcdhc.2022.826006.

Noninsulin-based antihyperglycemic medications in patients with diabetes and COVID-19: A systematic review and meta-analysis.

Nassar M, Abosheaishaa H, Singh A, Misra A, Bloomgarden Z J Diabetes. 2023; 15(2):86-96.

PMID: 36690377 PMC: 9934962. DOI: 10.1111/1753-0407.13359.

Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression.

Permana H, Yanto T, Hariyanto T Diabetes Res Clin Pract. 2022; 195:110205.

PMID: 36502891 PMC: 9731816. DOI: 10.1016/j.diabres.2022.110205.

References
1.
Fadini G, Morieri M, Longato E, Avogaro A . Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest. 2020; 43(6):867-869. PMC: 7103097. DOI: 10.1007/s40618-020-01236-2. View
2.
Iacobellis G . COVID-19 and diabetes: Can DPP4 inhibition play a role?. Diabetes Res Clin Pract. 2020; 162:108125. PMC: 7271223. DOI: 10.1016/j.diabres.2020.108125. View
3.
Jordan R, Adab P, Cheng K . Covid-19: risk factors for severe disease and death. BMJ. 2020; 368:m1198. DOI: 10.1136/bmj.m1198. View
4.
Rubino F, Amiel S, Zimmet P, Alberti G, Bornstein S, Eckel R . New-Onset Diabetes in Covid-19. N Engl J Med. 2020; 383(8):789-790. PMC: 7304415. DOI: 10.1056/NEJMc2018688. View
5.
Gentile S, Strollo F, Ceriello A . COVID-19 infection in Italian people with diabetes: Lessons learned for our future (an experience to be used). Diabetes Res Clin Pract. 2020; 162:108137. PMC: 7270733. DOI: 10.1016/j.diabres.2020.108137. View